DROPLET DIGITAL PCR AS A MOLECULAR TOOL FOR THE DETECTION OF THE EGFR T790M MUTATION IN NSCLC PATIENTS WITH THE EGFR ACTIVATING MUTATIONS
Durgut S, Salihefendić L, Pećar D, Čeko I, Mulahuseinović N, Izmirlija M, Konjhodžić R
*Corresponding Author: Selma Durgut, MD, ALEA Genetic Center, Olovska 67, 71000 Sarajevo, Bosnia and Herzegovina; Mob.: +38761904549, Email: selma.durgut@agc.ba
page: 21
|
|
REFERENCES
1. Garinet S, Laurent-Puig P, Blons H, Oudart J-B. Cur-
rent and Future Molecular Testing in NSCLC, What
Can We Expect from New Sequencing Technologies?
J Clin Med. 2018; 7(6):144.
2. Rodak O, Peris-Diaz MD, Olbromski M, Podhorska-
Okolow M, Dziegiel P. Current Landscape of Non-
Small Cell Lung Cancer: Epidemiology, Histological
Classification, Targeted Therapies, and Immunother-
apy. Cancers. 2021; 13(18):4705.
3. Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K,
Niho S et al. Dacomitinib versus gefitinib as first-line
treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a ran-
domised, open-label, phase 3 trial. Lancet Oncol.
2017; 18:1454-66.
4. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana
T, Chewaskulyong B, Lee KH et al. Osimertinib in
Untreated EGFR-Mutated Advanced Non-Small-Cell
Lung Cancer. N Engl J Med. 2018; 378(2):113-25.
5. Salihefendić L, Pećar D, Konjhodžić R. Validation of
CRC and NSCLC somatic mutations detected with NGS
using ddPCR. Genetics & Applications. 2019; 3(1):71-6.
6. Ohashi K, Maruvka YE, Michor F, Pao W. Epider-
mal growth factor receptor tyrosine kinase inhibitor-
resistant disease. J Clin Oncol. 2013; 31:1070–80.
7. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski
MF, Pao W et al. Analysis of tumor specimens at the
time of acquired resistance to EGFR-TKI therapy in
155 patients with EGFR-mutant lung cancers. Clin
Cancer Res. 2013; 19(8):2240-7.
8. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R,
Zakowski MF et al. Acquired resistance of lung ad-
enocarcinomas to gefitinib or erlotinib is associated
with a second mutation in the EGFR kinase domain.
PloS Med. 2005; 2(3):73.
9. Cunha Santos G, Shepherd FA, Tsao MS. EGFR Mu-
tations and Lung Cancer. Annual Review of Pathol-
ogy: Mechanisms of Disease, 2011; 6(1):49–69.
10. Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Wood-
ward BD, Lopez-Diaz FJ et al. Novel third-generation
EGFR tyrosine kinase inhibitors and strategies to
overcome therapeutic resistance in lung cancer. Can-
cer Res. 2019; 79(4):689-98.
11. Rodriguez J, Avila J, Rolfo C, Ruiz-Patino A, Russo
A, Ricaurte L et al. When Tissue is an Issue the Liquid
Biopsy is Nonissue: A Review. Oncol Ther. 2021;
9(1):89-110.
12. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli
A. Liquid biopsy: monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 2013; 10(8):472–484.
13. Droplet DigitalTM PCR Applications Guide (lab
handbook). Hercules, California: Bio-Rad Labora-
tories Inc ; 2017.
14. QIAamp ® Circulating Nucleic Acid Handbook.
Hilden, Germany: Qiagen, 2019.
15. QIAvac 24 Plus Handbook (lab handbook). Hilden,
Germany: Qiagen, 2010.
16. Qubit ® dsDNA HS Assay Kits (lab handbook). Carls-
bad, California: Life Technologies, 2015.
17. ddPCRTM EGFR T790M Screening Kit (lab handbook).
Hercules, California: Bio-Rad Laboratories Inc ; 2016.
18. Kim Y, Shin S, Lee KA. Exosome-based detection of
EGFR T790M in plasma and pleural fluid of prospec-
tively enrolled non-small cell lung cancer patients af-
ter first-line tyrosine kinase inhibitor therapy. Cancer
Cell Int. 2021; 21(50).
19. Ding PN, Becker T, Bray V, Chua W, Ma Y, Xu B,
Lynch D, de Souza P, Roberts T. Plasma next gen-
eration sequencing and droplet digital PCR-based
detection of epidermal growth factor receptor (EGFR)
mutations in patients with advanced lung cancer treat-
ed with subsequent-line osimertinib. Thorac Cancer.
2019; 10(10):1879-1884.
20. Kobayashi S, Boggon TJ, Dayaram T, Janne PA,
Kocher O, Meyerson M et al. EGFR mutation and
resistance of non-small-cell lung cancer to geftinib.
N Engl J Med. 2005; 352(8): 786-92.
21. Wang W, Song Z, Zhang Y. A Comparison of ddP-
CR and ARMS for detecting EGFR T790M status in
ctDNA from advanced NSCLC patients with acquired
EGFR-TKI resistance. Cancer Medicine. 2016; 6(1):
154-162.
22. Yoon HJ, Lee HY, Lee KS, Choi, Y-L, Ahn M-J,
Park K et al. Repeat biopsy for mutational analysis
of non-small cell lung cancers resistant to previous
chemotherapy: adequacy and complications. Radiol-
ogy. 2012; 265(3): 939-948.
23. Chouaid C, Dujon C, Do P, Monnet I, Madroszyk
A, Le Caer H et al. Feasibility and clinical impact of
re-biopsy in advanced non small-cell lung cancer: a
prospective multicenter study in a real-world setting
(GFPC study 12-01). Lung Cancer. 2014; 86(2):170-3.
24. Silveira C, Sousa AC, Janeiro A, Malveiro S, Teixeira
E, Brysch E et al. Detection and quantification of
EGFR T790M mutation in liquid biopsies by droplet
digital PCR. Transl Lung Cancer Res, 2021; 10(3):
1200-1208.
25. Jung A, Kirchner T. Liquid Biopsy in Tumor Genetic
Diagnosis. Deutsches Arzteblatt international, 2018;
115(10): 169–174.
26. Chan KCA, Jiang PY, Zheng YWL, Liao GJW, Sun H,
Wong J et al. Cancer genome scanning in plasma: de-
tection of tumor-associated copy number aberrations,
single-nucleotide variants, and tumoral heterogeneity
by massively parallel sequencing. Clin Chem, 2013;
59(1): 211–24.
27. Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J et
al. Plasma EGFR T790M ctDNA status is associated
with clinical outcome in advanced NSCLC patients
with acquired EGFR-TKI resistance. Scientific Re-
ports, 2016; 6,20913.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
